Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azd7789 + chemotherapy
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AZD7789 + chemotherapy refers to a combination therapy using **AZD7789 (sabestomig)** and chemotherapeutic agents. AZD7789 is a bispecific monoclonal antibody targeting both **PD-1** and **TIM-3** proteins, designed to enhance anti-tumor immunity by simultaneously blocking two negative immune checkpoints. This dual-targeting approach aims to improve activation of T cells against tumor cells and overcome resistance that may develop with single checkpoint inhibitors. Chemotherapy serves as the backbone treatment in cancer and can exert direct cytotoxic effects while also modulating the tumor microenvironment. The combination is under clinical investigation for relapsed/refractory classical Hodgkin lymphoma and potentially other advanced solid tumors, with AZD7789 administered via intravenous infusion.
- Brand names
- sabestomig
- Other names
- sabestomigazd7789azd-7789azd 7789
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on azd7789 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azd7789 + chemotherapy.